



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Friday, November 27, 2009

Intas Pharmaceuticals Ltd

[View the current Intas Pharmaceuticals Ltd Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/24697-Intas+Pharmaceuticals+Ltd.html)

(<http://www.bioportfolio.com/biocorporate/24697-Intas+Pharmaceuticals+Ltd.html>)

Contact Details:

**Chinubhai Centre, Ashram Road
Ahmedabad-
Gujarat
380 009
India**

Tel: 91-79-26576655
Fax: 91-79-26578862
Email: info@intaspharma.com

Decades ago, an enterprising young Medical Representative, H K Chudgar, dreamt of providing quality healthcare products to his country. At a time when India imported even foodgrains, this visionary wanted to manufacture world class medicines in the country. Armed with a degree in Pharmacy, this budding entrepreneur set up shop as a pharma trading agency in the 1960s and thus was Intas born. Never one to tread the beaten path, Mr. H K Chudgar decided to focus on niche therapeutic segments at a time when all others concentrated on the mass markets. Success for Intas came in the form of an anti-depressant that took the medical community by storm and then there was no looking back! Mr. Nimish Chudgar, Mr. Binish Chudgar and Dr. Urmish Chudgar joined the management team and together they led Intas into the psychiatric, neurological, cardiac and gastroenterological segments. So successful was this strategy of focusing on speciality segments that today Intas is among the fastest growing pharmaceutical companies in India.

As Intas grew and diversified into newer areas, Mr. H K Chudgar brought in a professional management team to help implement his Vision and today Intas reaps the twin benefits of entrepreneurial vision and professional management. This dynamic leadership has set the agenda for growth and Intas has been achieving an average annual growth of over 30% since 1990 with the turnover crossing the Rs. 1000 million mark in 1999. At the end of the financial year in 2001 it has increased to Rs. 1800 million.

Press Releases on Intas Pharmaceuticals Ltd:

["As an Industry, We've Been too Focused on Regulatory Approval," Says Solvay Pharmaceuticals Eric Rambeaux at the Pharma Marketing Summit.](#)

26th November,
2009

LONDON, November 26 /PRNewswire/ -- Rambeaux joined a host of other industry leaders at eye for pharma's 9th annual Pharma Marketing Summit 2009 conference in Berlin, where several key themes

[Onyx Pharmaceuticals Announces December 2009 Investor Events](#)

25th November, 2009

Onyx Pharmaceuticals, Inc.

EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7, SAN DIEGO, Nov. 25

[Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference](#)

25th November, 2009

Ardea Biosciences, Inc.

/PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the Piper

[iThemba Pharmaceuticals \(Pty\) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering](#)

25th November, 2009

DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals's service division and Pyxis Discovery announced today that they have signed a collaborative agreement

[Reportlinker Adds Cell/Tissue Culture Supplies - A Global Market Perspective](#)

25th November, 2009

Reportlinker

NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell/Tissue Culture Supplies - A Global Market Perspective <http://www>

BioNews Results for Intas Pharmaceuticals Ltd



- [AstraZeneca's Brilinta Shows Faster Onset/Offset Than Sanofi's Plavix, Phase 2 Study Reveals - Update](#)
RTTNews.com: Nov 18 2009 5:39PM Matching: intas pharmaceuticals
- [Pankaj Patel of Zydus Cadila new IPA president, Dr Prakash Mody vice-president](#)
PharmaBiz: Oct 1 2009 11:43AM Matching: intas pharmaceuticals

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to

your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

